Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Tolerability of Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer: A Randomized Controlled Multinational and Multicenter Clinical Trial

NCT04495309 is registered in ClinicalTrials.gov with University Hospital Schleswig-Holstein as lead sponsor.

NCT NCT04495309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04495309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Tolerability of Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer: A Randomized Controlled Multinational and Multicenter Clinical Trial
Lead sponsor
University Hospital Schleswig-Holstein
Phase
Not applicable
Overall status
Completed
Start date
March 5, 2021
Completion date
June 3, 2025
Enrollment
87 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer